The current financial score of Pluri Inc is 5.99. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 335.00K, representing a year-over-year decrease of 15.83%, while its net profit experienced a year-over-year decrease of 22.61%.
The current valuation score of Pluri Inc is 8.98. Its current P/E ratio is -0.38, which is -2.72% below the recent high of -0.37 and -392.15% above the recent low of -1.86.
No earnings forecast score is currently available for Pluri Inc. The Biotechnology & Medical Research industry's average is 8.11. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
The current price momentum score of Pluri Inc is 5.65. Currently, the stock price is trading between the resistance level at 1.51 and the support level at 0.85, making it suitable for range-bound swing trading.
The current institutional shareholding score of Pluri Inc is 3.00. The latest institutional shareholding proportion is 12.56%, representing a quarter-over-quarter decrease of 14.97%. The largest institutional shareholder is James Simons, holding a total of 18.32K shares, representing 0.00% of shares outstanding, with 73.63% decrease in holdings.
The current risk assessment score of Pluri Inc is 2.61. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.